Search research articles
Contact Us
Filters
Showing results (41-50 of 119) with videos related to
Page
of 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2021
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)
Krystal Bergin, Cameron Wellard, Elizabeth Moore, et al.
Blood
|
September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Simon J Harrison, Hang Quach, Emma Link, et al.
British Journal of Haematology
|
July 12, 2022
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Zoe McQuilten, Cameron Wellard, Elizabeth Moore, et al.
Future Oncology (London, England)
|
May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma
Sagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Scientific Reports
|
September 21, 2019
Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma
Sumita Ratnasingam, Joshua Casan, Jake Shortt, et al.
Transplantation and Cellular Therapy
|
November 13, 2022
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
Thomas G Martin, Marcelo Capra, Mohamad Mohty, et al.
Bone Marrow Transplantation
|
May 20, 2021
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)
Krystal Bergin, Cameron Wellard, Bradley Augustson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 5, 2025
Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry
Sarah Zhao, Cameron Wellard, Elizabeth M Moore, et al.
Annals of Hematology
|
April 22, 2020
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
Andrew Davies, Peter Trask, Judit Demeter, et al.
Leukemia & Lymphoma
|
July 21, 2025
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Cesar Rodriguez, Tulio Rodriguez, Alain Kentos, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 119) with videos related to
Sort By:
Page
of 12
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2021
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)
Krystal Bergin, Cameron Wellard, Elizabeth Moore, et al.
Blood
|
September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Simon J Harrison, Hang Quach, Emma Link, et al.
British Journal of Haematology
|
July 12, 2022
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Zoe McQuilten, Cameron Wellard, Elizabeth Moore, et al.
Future Oncology (London, England)
|
May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma
Sagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Scientific Reports
|
September 21, 2019
Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma
Sumita Ratnasingam, Joshua Casan, Jake Shortt, et al.
Transplantation and Cellular Therapy
|
November 13, 2022
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
Thomas G Martin, Marcelo Capra, Mohamad Mohty, et al.
Bone Marrow Transplantation
|
May 20, 2021
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)
Krystal Bergin, Cameron Wellard, Bradley Augustson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 5, 2025
Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry
Sarah Zhao, Cameron Wellard, Elizabeth M Moore, et al.
Annals of Hematology
|
April 22, 2020
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
Andrew Davies, Peter Trask, Judit Demeter, et al.
Leukemia & Lymphoma
|
July 21, 2025
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Cesar Rodriguez, Tulio Rodriguez, Alain Kentos, et al.
Page
of 12